NasdaqGM - Nasdaq Real Time Price USD

MediciNova, Inc. (MNOV)

1.4400 +0.0400 (+2.86%)

As of 10:07:06 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

MediciNova CEO Provides Shareholder Update

GlobeNewswire 21d ago

MNOV
+2.86%
^IXIC
MediciNova to Participate in the Maxim Growth Summit

GlobeNewswire 27d ago

MNOV
+2.86%
^IXIC
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

Benzinga 1mo ago

MNOV
+2.86%
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

InvestorsHub 1mo ago

MNOV
+2.86%
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Investing.com 1mo ago

MNOV
+2.86%
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire 1mo ago

MNOV
+2.86%
^IXIC
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewswire 1mo ago

MNOV
+2.86%
^IXIC
MediciNova to Participate in Two Investor Conferences in September

GlobeNewswire 1mo ago

MNOV
+2.86%
^IXIC
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

GlobeNewswire 3mo ago

MNOV
+2.86%
^IXIC
MediciNova CEO Provides Shareholder Update

GlobeNewswire 4mo ago

MNOV
+2.86%
^IXIC
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GlobeNewswire 4mo ago

MNOV
+2.86%
^IXIC
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswire 5mo ago

MNOV
+2.86%
^IXIC

Performance Overview

Return	MNOV	S&P 500 (^GSPC)
YTD	+13.36%	+11.39%
1-Year	-10.54%	+11.48%
3-Year	-21.43%	+76.60%

U.S. markets close in 5h 35m

MediciNova, Inc. (MNOV)

MediciNova CEO Provides Shareholder Update

MediciNova to Participate in the Maxim Growth Summit

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

MediciNova to Participate in Two Investor Conferences in September

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova CEO Provides Shareholder Update

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)